ReviewPharmaceutics2018
In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases.
Review in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 123 citations in OpenAlex.
- Multi-elemental fingerprinting of the human brain: distribution of toxic, essential, and rare earth elements across neocortical, limbic, and subcortical regions.Scientific reports · 2026Article
- Advances in Nose-to-Brain Delivery Systems for Effective Alzheimer's Disease Management.Current Alzheimer research · 2026Review
- Nanosystems for Intranasal Delivery of Therapeutics in Psychiatric Disorders.Current drug delivery · 2026Review
- Thermosensitive, mucoadhesive brivaracetam nasal gel: a promising strategy for targeted relief of epilepsy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Thermoreversible Ionogel for Enhanced Nose-to-brain Delivery of Tetrabenazine Hydrochloride: Optimization by Central Composite Design and In Vitro Ex Vivo Evaluation.AAPS PharmSciTech · 2025Article
- Recent Advances in Donepezil Delivery Systems via the Nose-to-Brain Pathway.Pharmaceutics · 2025Review
- Olfactory Drug Delivery in Rodents: Deposition and Pharmacokinetics.ACS pharmacology & translational science · 2025Article
- Intranasal Mucoadhesive In Situ Gel of Glibenclamide-Loaded Bilosomes for Enhanced Therapeutic Drug Delivery to the Brain.Pharmaceutics · 2025Article
- Preparation,Pharmaceutical nanotechnology · 2025Article
- Article
- Development and Optimization of Nasal Composition of a Neuroprotective Agent for Use in Neonatology after Prenatal Hypoxia.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Ion-activatedRecent advances in drug delivery and formulation · 2024Article
- Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A NovelApproach to Diagnosis and Treatment.Pharmaceutical nanotechnology · 2024Review
- Lamotrigine-Loaded Poloxamer-Based Thermo-Responsive Sol-Gel: Formulation, In Vitro Assessment, Ex Vivo Permeation, and Toxicology Study.Gels (Basel, Switzerland) · 2023Article
- Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation.Pharmaceutics · 2023Article
- Radiolabeled Risperidone microSPECT/CT Imaging for Intranasal Implant Studies Development.Pharmaceutics · 2023Article
- Intranasal Administration of Dolutegravir-Loaded Nanoemulsion-Based In Situ Gel for Enhanced Bioavailability and Direct Brain Targeting.Gels (Basel, Switzerland) · 2023Article
- Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy.Current neuropharmacology · 2023Review
- Nasal Absorption Enhancement of Mometasone Furoate Nanocrystal Dispersions.International journal of nanomedicine · 2023Article
- Transnasal-brain delivery of nanomedicines for neurodegenerative diseases.Frontiers in drug delivery · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of the nasal mucosa, transportation of the drugs to specific brain regions and determination of the required dose are factors that must be considered when designing these gels. This review will be focused on in situ-based gels that are used for the delivery of therapeutics via the nose-to-brain route, preclinical reports and challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.